Determination of Minimum Effective Dose and Optimal Dosing Schedule for Liposomal Curcumin in a Xenograft Human Pancreatic Cancer Model

CLAIRE M. MACH; LATA MATHEW; SCOTT A. MOSLEY; RAZELLE KURZROCK; JUDITH A. SMITH

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1.
Mean tumor volume over duration of the liposomal curcumin minimum effective dose (MED) finding study. The curves of the eight groups illustrating the mean tumor volume of mice non-treated, diluent alone, and different treatment arms of liposomal curcumin (1 mg/kg to 40 mg/kg) for the MiaPaCa2 pancreatic cancer xenograft model. The 20 mg/kg liposomal curcumin arm demonstrated a consistent greater inhibition of tumor growth compared to all other treatment arms.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Comparison of the final mean tumor weight at each dose liposomal curcumin dose level. The bars represent the final mean tumor weight for each of the eight groups of mice including non-treated, diluent alone, and different treatment arms of liposomal curcumin (1 mg/kg to 40 mg/kg) for the MiaPaCa2 pancreatic cancer xenograft model. Dash lines represent standard deviation for each treatment arm. The liposomal curcumin 20 mg/kg arm achieved greatest inhibition of tumor growth with the least variability compared to all other treatment arms.
Download figure
Open in new tab
Download powerpoint
Figure 3.
Mean tumor volume over duration of the study to determine the optimal dose regimen for liposomal curcumin. The four curves illustrate the mean tumor volume of liposomal curcumin 20 mg/kg given either once per week, once daily three times a week; once daily times five days per week or once daily every four days in the MiaPaCa2 pancreatic cancer xenograft model. The liposomal curcumin 20 mg/kg once daily three times a week versus once daily five times a week were similar and demonstrated better inhibition of tumor growth compared to the other treatment arms.